Investor Relations

Overview

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Events & Presentations

Upcoming

November 12, 2019 8:35 AM MST
Credit Suisse 28th Annual Healthcare Conference

October 29, 2019 8:00 AM EDT
Q3 2019 Incyte Corporation Earnings Conference Call

Prior

September 27, 2019 11:00 AM EDT
ESMO 2019: Pemigatinib Development Update

September 18, 2019 12:10 PM BST
Bank of America Merrill Lynch Global Healthcare Conference

September 10, 2019 12:55 PM EDT
Morgan Stanley 17th Annual Global Healthcare Conference

SEC Filings

Filing date Description Filing Group View

A statement of beneficial ownership of common stock by certain persons

3,4,5

An amendment to the SC 13G filing

3,4,5

An amendment to the SC 13G filing

3,4,5

Investor Contacts

Michael Booth D.Phil
Divisional VP of Investor Relations and Corporate Social Responsibility
Phone: 302.498.5914
E-mail: mbooth@incyte.com

Lauren Ayala
Senior Director, Investor Relations
Phone: 302.498.6141
E-mail: layala@incyte.com

Computershare
P.O. Box 43078
Providence, RI 02940-3078 Phone: 877.272.1536